Press Release

Beijing/Shenzhen, 28 December 2023 – Shenzhen Cispoly Bio-Tec Co., Ltd.（CISPOLY）, a leading technological innovator in women’s health, announced today its successful the Series B financing, raising over RMB 100 million. This substantial round was led by Prosperity7 Ventures, with unwavering support from existing shareholders. This financing underscores the market’s profound confidence in CISPOLY’s vision and its potential to revolutionize women’s healthcare.

Established with a relentless focus on technological innovation, CISPOLY has pioneered breakthroughs in pivotal areas of women’s disease detection and the Company intends to use the latest financing to propel its global expansion, fuel R&D, streamline product registrations, and amplify its consumer medical and public health initiatives.

CISPOLY has made significant strides in the field of women’s health, developing methylation detection tools for early-stage gynecological tumors and revolutionary products for women’s reproductive microbiota testing. In March this year, China’s National Medical Products Administration approved CISCER®, CISPOLY’s flagship product . It was spotlighted at the 9th National Colposcopy and Cervical Pathology (CSCCP) Conference and is endorsed in the “Chinese Cervical Cancer Standardization Blue Book” for multiple applications in cervical cancer treatment. CISPOLY is also expanding its product portfolio to include endometrial cancer screening products (CISENDO), which have completed clinical trials while the ovarian cancer methylation products (CISOVA) are in clinical trials.

In addition to its product development efforts, CISPOLY is also committed to clinical research. The company has launched national and provincial-level studies projects. With ongoing partnerships with top institutions across Southeast Asia and Europe, the Company is expanding its global footprint and academic influence.

This funding will catalyze CISPOLY’s growth in the global arena by diversifying its product suite and tapping the opportunities in public and consumer medicine sectors to address the diverse health needs of women worldwide.

Dr. Liu Pei, Founder of CISPOLY, said: “Our heartfelt gratitude goes to our shareholders for their trust. We will stay true to our mission, innovating for gynecological health and addressing clinical gaps and this funding will support our R&D efforts and help our reach both domestically and globally.”

Aysar Tayeb, Executive Managing Director of Prosperity7 Ventures, the diversified growth fund of Aramco Ventures, said: “We are thrilled to lead the Series B financing for CISPOLY. CISPOLY’s remarkable achievements in early-stage disease detection exemplify the kind of impactful ventures we aim to champion at Prosperity7 Ventures. We look forward to witness CISPOLY’s continued success as they expand their global footprint and enhance women’s health on a broader scale.”

Gu Shenghan, Executive Director of Sunland Fund, said, “Since Sunland’s initial investment in CISPOLY at its start-up stage, we have witnessed the remarkable execution capabilities of the founding team and their deep commitment to addressing various unmet diagnostic needs in the gynecology area. CISPOLY has been continuously introducing industry-leading innovative products that adhere to high standards of clinical research to drive widespread clinical application. We are delighted to find that CISPOLY’s product offerings are bridging gaps in the early screening and diagnosis methods for various gynecological diseases. Sunland’s investments in the gynecology and reproduction sector will continue to benefit patients from the clinical application of domestic innovative technology and products.”

About CISPOLY

CISPOLY is an innovation-driven high-tech enterprise focused on improving women’s health. The company is a pioneer in the early diagnosis of gynecological tumors. With exclusive technology and patent-protected markers at its core, the company has developed early diagnosis products for cervical cancer, ovarian cancer, and endometrial cancer, among other gynecological tumors, filling the gap in the field of women’s health. Headquartered in Beijing Daxing Biomedical Industry Base, CISPOLY has been focused on early diagnosis products of gynecological tumors and R&D, along with production and sales of automated testing equipment since its foundation. CISPOLY owns leading methylation detection technology and intellectual property rights for multiple markers. For more information, please visit http://en.cispoly.com/

About Prosperity7 Ventures

Prosperity7 Ventures (P7) is the diversified growth fund of Aramco Ventures, a subsidiary of Aramco, the world’s leading integrated energy and chemicals company. The fund’s name derives from ‘Prosperity Well’, the 7th oil well drilled in Saudi Arabia and the first to strike oil. Taking forward this pioneering history, P7 invests globally, with a long term-view, in breakthrough technologies and transformational business models that will bring prosperity and positive impact on a vast scale.

https://www.prosperity7vc.com/